Valproic acid induces manifestations of simultaneous dopamine enhancement and reduction in schizophrenia.
Lopez
Lina M
LM
Wassef
Adel A
AA
Molloy
Melissa S
MS
Williams
Nina G
NG
D000328:Adult; D001590:Benztropine / Q000627:therapeutic use; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D018682:GABA Agents / Q000627:therapeutic use*; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy*; D013997:Time Factors; D014635:Valproic Acid / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D018492:Dopamine Antagonists; D018682:GABA Agents; D018727:Muscarinic Antagonists; D001590:Benztropine; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D006220:Haloperidol; D004298:Dopamine